Investor ignoring brilliant biotech startup due to narrative gap
FUNDRAISING · INVESTOR PSYCHOLOGY

Why Investors Ignore Scientifically Brilliant Biotech Startups

Your science was never the reason for the pass. Here's what's actually happening inside an investor's head when brilliant biotech gets rejected.

9 MIN READREAD →
Biotech founder building pre-Series A narrative strategy
FUNDRAISING · STRATEGY

How to Build Your Pre-Series A Narrative (Before You Open the Data Room)

The 90 days before a Series A are the highest-leverage content window in a biotech founder's career. Here's the system to use them intentionally.

11 MIN READREAD →
LinkedIn for biotech founders
PLAYBOOK · LINKEDIN

The Biotech Founder's LinkedIn Playbook for 2026

A step-by-step system for biotech founders who want to attract investors, partners, and talent through LinkedIn, without becoming a full-time content creator.

12 MIN READREAD →
Content engine for biotech
STRATEGY · CONTENT

Why Every Biotech Needs a Content Engine (Not a Blog)

A blog is a graveyard. A content engine is a compounding asset. Here's the structural difference, and how to build one that survives founder transitions.

9 MIN READREAD →
Attract investors with content
FUNDRAISING

How Startups Attract Investors Using Content (Real Tactics)

Investors fund founders they recognize. Here's how to engineer that recognition before you even open the data room.

11 MIN READREAD →
Thought leadership on LinkedIn
AUTHORITY

How to Build Thought Leadership on LinkedIn (Without Posting Daily)

The myth of daily posting is killing biotech founders. Here's the high-leverage alternative, built around scientific credibility, not posting frequency.

8 MIN READREAD →
Social vs cold outreach
GROWTH

Why Social Media Is Replacing Cold Outreach in Biotech

Cold emails to biotech buyers convert at 0.4%. Inbound from LinkedIn authority converts at 8%. Here's why the math is shifting permanently, and what to do about it.

7 MIN READREAD →
AI search for biotech
AI · GEO/AEO

The Biotech AI Search Visibility Crisis (And How to Fix It)

Investors and BD execs are no longer Googling. They're asking ChatGPT. Here's what they're being told about you, and how to control the answer.

10 MIN READREAD →
Want These In Your Inbox?

One playbook a month. Built for biotech founders.

Get our deepest tactical breakdowns delivered before they go public. No spam. Unsubscribe anytime.